![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/novo-nordisk-offloads-preclinical-cancer-candidate-from-1-1b-forma-buyout-debiopharm/
https://www.biopharmadive.com/news/rigel-pharmaceuticals-leukemia-rezlidhia-fda-approval/637843/
https://www.globenewswire.com/news-release/2022/10/14/2534660/0/en/Novo-Nordisk-announces-the-completion-of-the-Forma-Therapeutics-acquisition.html
https://ir.formatherapeutics.com/news-releases/news-release-details/novo-nordisk-acquire-forma-therapeutics-and-expand-presence
https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-and-forma-therapeutics-announce-licensing-agreement-for-olutasidenib-a-novel-mutant-idh1-inhibitor-for-the-potential-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-301598297.html
https://www.fiercebiotech.com/biotech/rigel-hands-over-2m-formas-cancer-drug-awaits-fda-approval-decision